PROLIFIC: Prognostic Lung Fibrosis Consortium
PROLIFIC is a collaborative consortium advancing biomarker research and personalized treatment strategies for pulmonary fibrosis, using multi-assay panels and patient registry biosamples.
Funder: Pulmonary Fibrosis Foundation
Due Dates: Rolling (Consortium membership and research proposals)
Funding Amounts: No fixed award amount; support varies by project and consortium participation.
Summary: Consortium advancing biomarker research and personalized treatment strategies for pulmonary fibrosis through collaborative industry-academic partnerships.
Key Information: Open to new members from academia, industry, and non-profits; focus on translational biomarker research in IPF.
Description
The Prognostic Lung Fibrosis Consortium (PROLIFIC) is a collaborative initiative led by the Pulmonary Fibrosis Foundation (PFF) and Bristol Myers Squibb, bringing together pharmaceutical companies, foundations, and academic institutions. PROLIFIC’s mission is to accelerate scientific discovery and drug development in pulmonary fibrosis—particularly idiopathic pulmonary fibrosis (IPF)—by identifying and validating blood-based protein biomarkers. The consortium’s work centers on developing and testing multi-assay biomarker panels using biosamples from the PFF Registry, with the goal of predicting patient prognosis and guiding the development of personalized treatment strategies.
PROLIFIC’s approach is unique in its open, cooperative model, encouraging participation from new academic, biotech, and pharmaceutical partners. The consortium provides access to a harmonized biomarker assay platform and leverages the PFF Registry’s large, well-characterized patient cohort, enabling robust translational and clinical research.
